Mechanistically, the cannabinoid receptor CB2 can interact with TLR4 and inhibit the pro-inflammatory signaling of TLR4, while lack of MGLL promotes CB2/TLR4-dependent the M2 phenotype in TAMs, thereby inhibiting the function of tumor-related CD8+ T cells and promoting tumor progression. This evidence concerns the gene CNR2 and neoplasm.